共 14 条
- [1] Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition[J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (08) : 3130 - 3144Cherkassky, LeonidMorello, AuroreVillena-Vargas, JonathanFeng, YangDimitrov, Dimiter S.Jones, David R.Sadelain, MichelAdusumilli, Prasad S.
- [2] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte[J]. BLOOD, 2010, 116 (12) : 2040 - 2045Coiffier, BertrandThieblemont, CatherineVan Den Neste, EricLepeu, GerardPlantier, IsabelleCastaigne, SylvieLefort, SophieMarit, GeraldMacro, MargaretSebban, CatherineBelhadj, KarimBordessoule, DominiqueFerme, ChristopheTilly, Herve
- [3] Crump M, 2016, J CLIN ONCOL S, V34
- [4] Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Galon, JeromeRossi, JohnTurcan, SarahDanan, CorinneLocke, Frederick LundryNeelapu, Sattva SwarupMiklos, David BernardBartlett, Nancy L.Jacobson, Caron AlyceBraunschweig, IraOluwole, Olalekan O.Siddiqi, TanyaLin, YiTimmerman, JohnReagan, Patrick MichaelLekakis, Lazaros J.
- [5] Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy[J]. BLOOD, 2016, 127 (20) : 2406 - 2410Gardner, RebeccaWu, DavidCherian, SindhuFang, MinHanafi, Laila-AichaFinney, OliviaSmithers, HannahJensen, Michael C.Riddell, Stanley R.Maloney, David G.Turtle, Cameron J.
- [6] Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy[J]. MOLECULAR THERAPY, 2017, 25 (10) : 2245 - 2253Kochenderfer, James N.Somerville, Robert P. T.Lu, TangyingYang, James C.Sherry, Richard M.Feldman, Steven A.McIntyre, LoriBot, AdrianRossi, JohnLam, NorrisRosenberg, Steven A.
- [7] Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19[J]. BLOOD, 2010, 116 (20) : 4099 - 4102Kochenderfer, James N.Wilson, Wyndham H.Janik, John E.Dudley, Mark E.Stetler-Stevenson, MaryaliceFeldman, Steven A.Maric, IrinaRaffeld, MarkNathan, Debbie-Ann N.Lanier, Brock J.Morgan, Richard A.Rosenberg, Steven A.
- [8] B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period[J]. LEUKEMIA & LYMPHOMA, 2008, 49 (01) : 152 - 153Lim, Seah H.Esler, William V.Zhang, YanaZhang, JianPeriman, Phillip O.Burris, ColleenTownsend, Mary
- [9] Locke FL, 2017, CANCER RES, V77, pCT019
- [10] Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma[J]. MOLECULAR THERAPY, 2017, 25 (01) : 285 - 295Locke, Frederick L.Neelapu, Sattva S.Bartlett, Nancy L.Siddiqi, TanyaChavez, Julio C.Hosing, Chitra M.Ghobadi, ArminBudde, Lihua E.Bot, AdrianRossi, John M.Jiang, YizhouXue, Allen X.Elias, MegAycock, JeffWiezorek, JeffGo, William Y.